No Data
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst David Amsellem maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $24
UBS analyst Ashwani Verma maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 47.
Express News | Teva Pharmaceuticals : UBS Raises Target Price to $24 From $22
Express News | UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $24
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 41.26% UBS $22 → $24 Maintains Buy 06/27/2024 35.37% Jefferies $19 → $23 Maintains Buy 06/05/20
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
loading...